Pay in 4 interest-free payments of $6.29 Learn more
Ships within 48 hours · Estimated delivery Oct 9 - Oct 14
Setting short-term goals, tracking progress through photos or measurements, and celebrating small victories help maintain motivation
In June, Eli Lilly has announced Phase II results of its SYNERGY-NASH trial in which 54.9% of patients on its dual GLP-1/GIP receptor agonist tirzepatide 5 mg, 51.3% of patients on tirzepatide 10 mg and 51% of patients on tirzepatide 15 mg saw their fibrosis decreaseby at least one stage without their metabolic dysfunction-associated steatohepatitis (MASH) worsening
Online portal Chat with support, track your weight loss, manage your refills, shipment updates and more, 100% online
Think of it as part of the therapy
US$ 27.56
US$ 29.64
US$ 27.29
US$ 23.94
